27 completed, 2 recruiting, 1 active not recruiting, 1 terminated. 14 Phase 3, 12 Phase 2, 2 Not applicable, 2 Phase 1, 1 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 14 | Completed 11, Recruiting 2, Terminated 1 |
| Phase 2 | 12 | Completed 12 |
| Not applicable | 2 | Active not recruiting 1, Completed 1 |
| Phase 1 | 2 | Completed 2 |
| Phase 4 | 1 | Completed 1 |
Follow AGO Study Group: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Niraparib vs Niraparib Plus Bevacizumab in Patients With Platinum/Taxane-based Chemotherapy in Advanced Ovarian Cancer Carboplatin, Paclitaxel, Bevacizumab - Ovarian Cancer, Fallopian Tube Cancer | Phase 3 | Recruiting | AGO Study Group | 970 | 2022-09-13 | 2025-09-10 |
| MAintenance Therapy With Aromatase Inhibitor in Epithelial Ovarian Cancer (MATAO) Letrozole 2.5mg, Placebo - Ovarian Neoplasm Epithelial, Fallopian Tube Neoplasms | Phase 3 | Recruiting | Swiss GO Trial Group | 540 | 2020-11-05 | 2025-09-29 |
| Platinum-based Chemotherapy With Atezolizumab and Niraparib in Patients With Recurrent Ovarian Cancer Placebo, Carboplatin, Paclitaxel - Recurrent Ovarian Carcinoma | Phase 3 | Completed | Grupo Español de Investigación en Cáncer de Ovario | 417 | 2018-11-21 | 2024-08-30 |
| Platinum Chemotherapy Plus Paclitaxel With Bevacizumab and Atezolizumab in Metastatic Carcinoma of the Cervix Atezolizumab, Bevacizumab, Cisplatin/Carboplatin - Carcinoma of the Cervix, Stage IVB | Phase 3 | Completed | Grupo Español de Investigación en Cáncer de Ovario | 410 | 2018-09-25 | 2026-04-21 |
| Trial on Radical Upfront Surgery in Advanced Ovarian Cancer PDS (Primary Debulkdung Surgery), 6 cycles of standard chemotherapy, Timing of surgery after 3 cycles of standard NACT, IDS - Ovarian Cancer | Not applicable | Active not recruiting | AGO Study Group | 797 | 2016-07-01 | 2025-10-03 |
| A Study of Palbociclib in Addition to Standard Endocrine Treatment in Hormone Receptor Positive Her2 Normal Patients With Residual Disease After Neoadjuvant Chemotherapy and Surgery Palbociclib PD-0332991, Placebo - Breast Cancer, Hormonreceptor Positive | Phase 3 | Completed | GBG Forschungs GmbH | 1250 | 2013-10-30 | 2023-12-12 |
| Evaluation of Optimal Treatment Duration of Bevacizumab Combination With Standard Chemotherapy in Patients With Ovarian Cancer Bevacizumab, Paclitaxel, Carboplatin - Genital Diseases, Female, Ovarian Diseases | Phase 3 | Completed | AGO Study Group | 927 | 2011-11-01 | 2022-07-20 |
| Efficacy,Tolerability,Safety of Temsirolimus in Women With Platinum-refractory Ovarian Carcinoma or Advanced Endometrial Carcinoma Temsirolimus - Genital Diseases, Female, Ovarian Diseases | Phase 2 | Completed | AGO Study Group | 47 | 2011-10-01 | 2016-02-29 |
| Chemo- and Radiotherapy in Epithelial Vulvar Cancer Radio/Chemotherapy in Node Positive Advanced Vulvar Cancer | Completed | AGO Study Group | 1618 | 2011-02-01 | 2016-05-10 | |
| Study Comparing Tumor Debulking Surgery Versus Chemotherapy Alone in Recurrent Platinum-Sensitive Ovarian Cancer Tumor Debulking Surgery (surgery in recurrent ovarian disease) - Fallopian Tube Cancer, Ovarian Cancer | Not applicable | Completed | AGO Study Group | 408 | 2010-07-01 | 2022-01-25 |
| Multicenter Trial With PegLiposomal Doxorubicin and Carboplatin Combination Chemotherapy in Gynecological Sarcomas and Mixed Epithelial-Mesenchymal Tumors PegLiposomal Doxorubicin, Carboplatin - Mesenchymal Tumor, Carcinosarcoma | Phase 2 | Completed | AGO Study Group | 41 | 2008-06-01 | 2017-02-14 |
| Antitumoral Activity and Safety of AEZS-108 in Women With LHRH Receptor Positive Gynecological Tumors AEZS-108 - Ovarian Cancer, Endometrial Cancer | Phase 2 | Completed | AEterna Zentaris | 85 | 2007-12-01 | 2011-12-13 |
| Bevacizumab, Everolimus (RAD001), and Lapatinib as Neoadjuvant Chemotherapy Regimes for Primary Breast Cancer epirubicin - cyclophosphamide / docetaxel, epirubicin - cyclophosphamide / docetaxel + bevacizumab, paclitaxel - Breast Cancer | Phase 3 | Completed | GBG Forschungs GmbH | 2600 | 2007-10-01 | 2016-02-10 |
| Randomized Multicenter Trial With SU11248 Evaluating Dosage,Tolerability,Toxicity and Effectiveness of a Multitargeted Receptor Tyrosine Kinase Inhibitor Sunitinib, SUNITINIB - Platinum Refractory Epithelial Ovarian Cancer, Primary Cancer of the Peritoneum | Phase 2 | Completed | AGO Study Group | 73 | 2007-09-01 | 2014-03-07 |
| Validation of a Score of Predictive Factors for Complete Resection in Platinum-sensitive Recurrent Ovarian Cancer Ovarian Cancer | Completed | AGO Study Group | 122 | 2006-09-01 | 2011-02-15 | |
| Comparison of Paclitaxel/Carboplatin and Lonafarnib to Paclitaxel/Carboplatin for First-line Treatment of Ovarian Cancer Lonafarnib - Epithelial Ovarian Cancer | Phase 2 | Completed | AGO Study Group | 105 | 2006-01-01 | 2012-06-29 |
| Caelyx Plus Carboplatin Versus Paclitaxel Plus Carboplatin in Patients With Epithelial Ovarian Cancer in Late Relapse Pegylated liposomal doxorubicin, Carboplatin, Paclitaxel - Ovarian Cancer, Fallopian Tube Cancer | Phase 3 | Completed | ARCAGY/ GINECO GROUP | 976 | 2005-04-01 | 2014-01-10 |
| Randomized, Multicenter, 2-Dose Level. Open-Label, Phase IIa Study With the Intraperitoneally Infused Trifunctional Bispecific Antibody Removab(TM) (Anti-EpCAM x Anti-CD3) to Select the Better Dose Level in Platinum Refractory Epithelial Ovarian Cancer Patients anti-EpCAM x anti-CD3 (removab) - Ovarian Cancer, Fallopian Tube Neoplasms | Phase 2 | Completed | AGO Study Group | 44 | 2004-05-01 | 2006-11-08 |
| Reinduction Chemotherapy Containing Carboplatin and Paclitaxel With or Without Epoetin Alpha in Recurrent Platinum Sensitive Ovarian Cancer, Cancer of the Fallopian Tube or Peritoneum paclitaxel, carboplatin, epoetin alpha - Epithelial Ovarian Cancer, Fallopian Tube or Peritoneum, Platinum Sensitve Relapse | Phase 3 | Terminated | AGO Study Group | 300 | 2004-02-01 | 2005-09-19 |
| Use of ACA 125 in Patients With Ovarian Cancer: Safety and Immune Response ACA 125 - Ovarian Cancer, Fallopian Tube Neoplasms | Phase 1 / Phase 2 | Completed | AGO Study Group | 36 | 2003-07-01 | 2006-10-02 |
Showing 20 of 31. Sign in to see all of them.
Ovarian Neoplasms (19) · Fallopian Tube Neoplasms (13) · Carcinoma, Ovarian Epithelial (7) · Peritoneal Neoplasms (4) · Uterine Cervical Neoplasms (4) · Breast Neoplasms (3) · Endometrial Neoplasms (3) · Recurrence (3) · Anemia (2) · Genital Diseases, Female (2) · Neoplasms (2) · Ovarian Diseases (2) · Carcinoma (1) · Carcinosarcoma (1) · Disease Progression (1)
Carboplatin (12) · Paclitaxel (11) · Bevacizumab (4) · Gemcitabine (4) · liposomal doxorubicin (4) · Cisplatin (2) · Topotecan (2) · Trastuzumab (2) · atezolizumab (2) · niraparib (2) · Brachytherapy (1) · CP protocol (1) · Cyclophosphamide (1) · Docetaxel (1) · Drugs, Generic (1)
Germany (28) · France (8) · Austria (5) · Italy (5) · Denmark (4) · Norway (4) · Spain (4) · Sweden (4) · United States (4) · Belgium (3) · United Kingdom (3) · Canada (2) · Japan (2) · South Korea (2) · Australia (1)
Andreas du Bois, MD, PhD (3) · Jacobus Pfisterer, MD (2) · Jacobus Pfisterer, Prof. Dr. (2) · Michael Untch, MD, Prof. (2) · Philipp Harter, MD (2) · Uwe Wagner, Prof.Dr. (2) · Ana Oaknin, MD PhD (1) · Andreas du Bois, MD PhD (1) · Andreas du Bois, Prof. Dr. (1) · Angel J. Lacave, MD, PhD (1) · Annette Hasenburg, PD Dr. (1) · Christian Jackisch, MD, PhD (1) · E. Pujade-Lauraine, MD, PhD (1) · Eric Pujade-Lauraine, MD, PhD (1)
PMID 37185961, PMID 16882940, PMID 16966687, PMID 15661234, PMID 15839957, PMID 17161453, PMID 17910981, PMID 20733132, PMID 21270612, PMID 21410972, PMID 21733566, PMID 22257523, PMID 22276820, PMID 22377563, PMID 22508812, PMID 22564713, PMID 25223482, PMID 25618900, PMID 29543566, PMID 29743148, PMID 29791287, PMID 31420412, PMID 31645423, PMID 33318079, PMID 33793299, PMID 34874631, PMID 35524184, PMID 36332161, PMID 37935524, PMID 38048793, PMID 39292975, PMID 40022844, PMID 40209141, PMID 40968753, PMID 42025846
2018 (2), 2019 (1)